Repligen Corp (NASDAQ:RGEN)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.

Recs

0
Player Avatar TerryHoodSr (53.89) Submitted: 5/27/2013 3:30:28 PM : Outperform Start Price: $7.87 RGEN Score: +125.14

3 YR rev growth 34%

Featured Broker Partners


Advertisement